Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 2
1958 1
1966 2
1969 2
1970 1
1971 1
1972 1
1973 1
1974 3
1975 2
1977 1
1978 1
1979 1
1980 2
1981 2
1982 4
1983 3
1984 4
1985 9
1986 1
1987 4
1988 2
1989 4
1990 5
1991 4
1992 6
1993 3
1994 10
1995 8
1996 12
1997 9
1998 7
1999 9
2000 9
2001 11
2002 11
2003 21
2004 15
2005 17
2006 21
2007 20
2008 22
2009 24
2010 31
2011 18
2012 21
2013 26
2014 21
2015 24
2016 23
2017 22
2018 21
2019 24
2020 21
2021 24
2022 20
2023 16
2024 14
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. Among authors: mark tm. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Levin MD, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Spencer A. Sonneveld P, et al. Among authors: mark tm. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. doi: 10.1200/JCO.21.02734. Epub 2022 Nov 22. J Clin Oncol. 2023. PMID: 36413710 Free PMC article. Clinical Trial.
Wound Bed Preparation 2024: Delphi Consensus on Foot Ulcer Management in Resource-Limited Settings.
Smart H, Sibbald RG, Goodman L, Ayello EA, Jaimangal R, Gregory JH, Akita S, Alavi A, Armstrong DG, Arputhanathan H, Bruwer F, Caul J, Chan B, Cronje F, Dofitas B, Hamed J, Harley C, Heil J, Hill M, Jahnke D, Kalina D, Kodange C, Kotru B, Kozody LL, Landis S, LeBlanc K, MacDonald M, Mark T, Martin C, Mayer D, Murphy C, Nair H, Orellana C, Ostrow B, Queen D, Rainville P, Rajhathy E, Schultz G, Somayaji R, Stacey MC, Tariq G, Weir G, Whiteside C, Yifter H, Zacharias R. Smart H, et al. Among authors: mark t. Adv Skin Wound Care. 2024 Apr 1;37(4):180-196. doi: 10.1097/ASW.0000000000000120. Epub 2024 Feb 13. Adv Skin Wound Care. 2024. PMID: 38354304 Review.
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Steffensen LA, Tindberg AM, Wollenberg A. Simpson EL, et al. Among authors: mark t. Am J Clin Dermatol. 2023 Nov;24(6):939-952. doi: 10.1007/s40257-023-00806-3. Epub 2023 Sep 8. Am J Clin Dermatol. 2023. PMID: 37682422 Free PMC article.
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Thieblemont C, et al. Among authors: mark t. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25. Leukemia. 2024. PMID: 39322711 Free PMC article.
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM, Weidinger S. Silverberg JI, et al. Among authors: mark t. Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. Am J Clin Dermatol. 2022. PMID: 35857179 Free PMC article. Clinical Trial.
Novel Induction Regimens in Multiple Myeloma.
Runcie KD, Mark TM. Runcie KD, et al. Among authors: mark tm. Curr Hematol Malig Rep. 2015 Dec;10(4):388-94. doi: 10.1007/s11899-015-0282-1. Curr Hematol Malig Rep. 2015. PMID: 26275667 Review.
579 results